Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

774
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
774
Drug Therapy01:28

Drug Therapy

232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
232
Bipolar Disorder01:30

Bipolar Disorder

602
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
602
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

275
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
275
Classification of Neurotransmitters01:30

Classification of Neurotransmitters

4.9K
Neurotransmitters play a crucial role in the communication between neurons in the autonomic nervous system. Neurons in the autonomic nervous system can be cholinergic or adrenergic depending on the neurotransmitters synthesized. Cholinergic neurons use acetylcholine as their primary neurotransmitter. This includes all the preganglionic fibers of the sympathetic and pre- and postganglionic fibers of the parasympathetic nervous systems. In addition, neurons of the somatic nervous system also use...
4.9K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Converting negative symptom dimension scores across SANS and PANSS.

Schizophrenia research·2026
Same author

Longitudinally altered default mode network and insula multimodal brain pattern in end-stage renal disease during sustained hemodialysis treatment.

iScience·2026
Same author

Cerebellar structure is abnormal in schizophrenia and deviates from bipolar disorder.

NeuroImage. Clinical·2026
Same author

Individualized cortical gradient and network topology reveal symptom-linked disruptions and neurobiological subtypes in schizophrenia.

medRxiv : the preprint server for health sciences·2026
Same author

Multiscale characterization of cortical signatures in positive and negative schizotypy: a worldwide ENIGMA study.

Molecular psychiatry·2026
Same author

NeuroMark-SZ: A Holistic Resting-State-fMRI-Based Model for Divergent Functional Circuitry in Schizophrenia.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jan 9, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.2K

Template-driven Dynamic Functional Network Connectivity Predicts Medication Class Response for Major Depression and

Bradley T Baker, Elizabeth Osuch, Scott Langenecker

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
    |December 3, 2025
    PubMed
    Summary

    This study introduces a novel template-driven method for analyzing brain connectivity in major depression and bipolar disorder. This approach enhances prediction of medication response, aiding clinical decision-making for mood disorders.

    More Related Videos

    Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
    08:15

    Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

    Published on: June 6, 2025

    497
    Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
    07:58

    Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

    Published on: February 24, 2023

    798

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
    05:19

    Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

    Published on: July 7, 2023

    3.2K
    Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
    08:15

    Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

    Published on: June 6, 2025

    497
    Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
    07:58

    Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

    Published on: February 24, 2023

    798

    Area of Science:

    • Neuroscience
    • Medical Imaging
    • Computational Psychiatry

    Background:

    • Treating major depression and bipolar disorder is challenging due to complex symptoms and variable medication responses.
    • Neuroimaging, particularly functional magnetic resonance imaging (fMRI), offers potential for objective diagnostic and treatment insights.
    • Dynamic functional network connectivity (dFNC) analysis of fMRI data can reveal subtle physiological changes.

    Purpose of the Study:

    • To develop and validate a novel template-driven method for generating robust dynamic functional network connectivity (dFNC) features.
    • To assess the efficacy of these dFNC biomarkers in predicting medication class response for major depression and bipolar disorder.
    • To expand the repertoire of biomarkers for studying mood disorder treatment variations.

    Main Methods:

    • A novel template-driven approach was used to derive dFNC features from neuroimaging data.
    • A template of dynamic states was created from a large dataset of non-affected individuals.
    • Continuous state-contribution time series were generated, expanding on standard dFNC methods.

    Main Results:

    • The template-driven dFNC approach yielded robust and replicable biomarkers.
    • The derived biomarkers demonstrated high predictive performance for identifying medication class.
    • The method successfully expanded the set of available biomarkers for mood disorder research.

    Conclusions:

    • The developed template-driven dFNC method provides a novel way to generate clinically relevant biomarkers.
    • These biomarkers show potential for clinical decision support in prescribing medication for major depression and bipolar disorder.
    • This approach can aid in understanding and personalizing treatment for mood disorders.